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Abstract
Background: Studies investigating the use of platelet–rich plasma (PRP) in the treatment of intrabony defects have
yielded mixed results. The aim of our study was to evaluate the efficacy of PRP by comparing clinical attachment
level (CAL) and pocket depth (PD) for patients who received PRP as an adjunct to periodontal intrabony defect
therapy with those for patients who did not. We also analyzed the influence of guided tissue regeneration (GTR)
and different study designs (parallel and split–mouth studies) on the clinical outcomes of intrabony defects.
Methods: We performed a systematic review of articles published in any language up to June 7, 2015 by searching
PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. We included only
randomized controlled clinical trials (RCTs) that compared clinical outcomes between patients who received
PRP as an adjunct to periodontal intrabony defect therapy and patients who did not. We combined data
from randomized trials to assess clinical outcomes using a random–effects model.
Results: Of the 307 abstracts that were initially identified, 12 RCTs related to the treatment of periodontal
intrabony defects were included in the final analysis. Clinically and significantly greater CAL gains and PD
reductions were observed in subjects who received PRP as an adjunct to periodontal intrabony defect
therapy than in subjects who did not (CAL: WMD 0.76 mm, 95 % CI = 0.34 to 1.18 mm, P = 0.0004; PD: WMD
0.53 mm, 95 % CI = 0.21 to 0.85 mm, P = 0.001). Subgroup meta-analyses of patients who underwent GTR
demonstrated that this approach did not significantly affect treatment outcomes (CAL: WMD 0.08 mm, 95 % CI = −0.30
to 0.46 mm, P = 0.67), as indicated by a comparison with patients who did not undergo GTR (CAL: WMD 1.
22 mm, 95 % CI = 0.88 to 1.57 mm, P < 0.00001). Univariate meta-regression analyses revealed that the use of
GTR explained the heterogeneity among the included studies (P < 0.05).
Conclusions: Within its limitations, this review suggests that PRP may be beneficial as an adjunct to graft
materials for the treatment of periodontal intrabony defects, except in cases involving the use of GTR.
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Background
Periodontitis is a disease of the periodontium character-
ized by an irreversible loss of attachment to the connect-
ive tissue and supporting alveolar bone [1]. Periodontitis
will continue to progress if no intervention is under-
taken and will ultimately result in early tooth loss.
Current therapeutic modalities to restore the disrupted
periodontium, such as conventional open flap debride-
ment (OFD), have shown limited potential to achieve
the desired results [2].
The key to tissue regeneration is to stimulate a cascade
of healing events that, if coordinated, can result in the
completion of integrated tissue formation. Such modula-
tors include the use of growth factors, the application of
extracellular matrix proteins and attachment factors,
and the use of bone morphogenetic proteins [3]. The po-
tential role of polypeptide growth factors (PGFs) in peri-
odontal regeneration is currently a focus of research.
Among the PGFs, platelet-derived growth factor (PDGF)
and transforming growth factor-β (TGF-β) have been
the most extensively studied in terms of periodontal re-
generation. These components are known to facilitate
bone regeneration after bone grafting by enhancing
neoangiogenesis, cellular chemotaxis and mitosis, pro-
moting stem cell proliferation, and increasing osteocon-
duction via the fibrin network [4]. For decades, there has
been a growing interest in the use of platelet-rich plasma
(PRP) for the treatment of periodontal intrabony defects.
PRP is a concentrated source of autologous platelets that
is enriched with several growth factors, including PDGF,
transforming growth factor-1 (TGF-1), transforming
growth factor-2 (TGF-2), vascular endothelial growth
factor (VEGF), insulin-like growth factor-1 (IGF-1),
insulin-like growth factor-2 (IGF-2), fibroblast growth
factor-β (FGF-β) and epithelial growth factor (EGF). All
of these hormones are secreted by platelets to initiate
wound healing [5]. Some studies [6–11] have sug-
gested that following coagulation, the PRP preparation
exhibits a “sticky consistency” that may improve the
clinical handling properties of the combination of
PRP and the graft material, thereby enhancing wound
stability.
Recently published systematic reviews and meta-
analyses [12, 13] on this topic have demonstrated the
beneficial effect of PRP in the treatment of intrabony de-
fects. However, high heterogeneity among the examined
studies rendered it difficult to draw clear interpretations.
We will explore the sources of heterogeneity between
studies through subgroup meta-analyses and a meta-
regression. The aim of our study was to evaluate the effi-
cacy of PRP in the surgical treatment of periodontal
intrabony defects by comparing clinical outcomes be-
tween patients who received PRP as an adjunct to peri-
odontal intrabony defect therapy and those who did not.
Methods
Search strategy
This systematic review was performed in accordance
with the guidelines of the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) state-
ment and the Cochrane Handbook [14, 15]. Four elec-
tronic databases (PubMed, Embase, Web of Science and
the Cochrane Central Register of Clinical Trials) were
searched using the following keywords: (“platelet rich
plasma” OR “PRP” OR “autologous platelet concentrate”
OR “platelet gel”) AND (“periodontal atrophy” OR “peri-
odontal defects” OR “intrabony defects” OR “infrabony
defect” OR “periodontal osseous defects”). The search
was limited to clinical trials involving human subjects
with no restrictions with respect to language. All data-
bases were searched from their inception to June 2015.
The bibliographies of all original research and review ar-
ticles identified to be relevant to the subject were
scanned for possible additional studies. The literature
search was performed by two examiners (X.H. and J.Y.).
Study selection criteria
Studies were selected if they fulfilled the following inclu-
sion criteria: 1) a randomized controlled clinical trial
(RCT) in which an intervention group receiving PRP
was compared with a control group not receiving PRP;
2) the patients included in the RCT had no systemic ill-
ness or abnormal platelet counts that could affect the
clinical outcome of periodontal therapy; and 3) a follow-
up period of at least 6 months.
The exclusion criteria included the following: 1) an in-
adequate comparison of the results of PRP for the treat-
ment of periodontal intrabony defects; 2) PRP
administered to both the intervention and control
groups; 3) the use of a biologic material that would ham-
per meaningful comparisons; or 4) other article types,
such as reviews, case reports, and animal studies.
Data extraction and quality assessment
The characteristics of the included studies were ex-
tracted by two reviewers (X.H. and J.Y.), and the relevant
data from the studies that met the inclusion criteria were
extracted independently. Any discrepancy was resolved
by discussion. The following characteristics of each in-
cluded study were recorded: characteristics of the trial
(first author’s last name, publication year, study design,
number of patients, number of defect sites, length of
follow-up, and evaluation indicators); intervention (types
of bone substitutes and parameters of PRP preparation
and application); and outcome measures.
The risk of bias was evaluated independently by two
reviewers (A.A. and Y.L.), and any disagreements were
resolved by a third reviewer (X.H.). The quality of the
selected RCTs was assessed using the Risk of Bias tool
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according to the Cochrane Handbook for Systematic Re-
views of Interventions (Version 5.1.0) [15]. The selected
RCTs were assessed using the following criteria: se-
quence generation, allocation concealment, masking of
the examiner, incomplete outcome data, free of selective
outcome reporting, and other sources of bias.
Outcome variables and statistical analyses
For studies evaluating the effect of PRP in the treatment
of intrabony defects, the change in CAL from the initial
diagnosis to the final follow-up was our primary out-
come variable. The change in probing depth between
baseline and the final follow-up was considered the sec-
ondary outcome variable.
The meta-analysis was performed on similar studies
that only evaluated the difference between the interven-
tion and control groups regarding the adjunctive use of
PRP. First, the pooled weighted mean difference of the
outcome variables was estimated using Review Manager
Version 5.3 (The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark). The
results are expressed as the mean differences for con-
tinuous outcomes using the random-effects model. For-
est plots were constructed to graphically represent the
difference in outcomes between the intervention and
control groups. The significance level for this meta-
analysis model was 0 · 05. The statistical heterogeneity
among the included studies was evaluated using the chi-
square (χ2) and I2 tests. Publication bias was evaluated
through funnel plots and Egger’s test using STATA soft-
ware (STATA/SE 12; Stata Corp, College Station, TX,
USA). For this test, a P value of less than 0.1 shows sig-
nificant asymmetry and therefore publication bias [16].
Second, we performed a subgroup meta-analysis of CAL
to determine the effects of the use of GTR and of differ-
ent study designs. We performed subgroup analyses for
these two specific moderators due to their well-known
clinical implications and statistical effects [17, 18]. On
the one hand, a prior meta-analysis [17] demonstrated
that the proven efficacy of GTR in regenerative peri-
odontal procedures could mask the effects of a platelet
concentrate. On the other hand, a study [18] published
in 2009 suggested that it is advisable to meta-analyze
split-mouth and parallel-group trials separately as sub-
groups to investigate their systematic differences.
Third, we explored other sources of heterogeneity in
studies through a meta-regression analysis [19, 20]. We
performed a separate univariate meta-regression analysis
using STATA software; multivariate meta-regression
analysis was not performed due to the inclusion of an
inadequate number of studies. A random-effects model
with a restricted maximum-likelihood estimator was
used to synthesize effect size across studies. The vari-
ables we selected included not only the use of GTR and
study design but also the type of control (allograft, xeno-
graft, or artificial bone), which was reported in all of the
included studies and may be a potential source of
heterogeneity.
Results
A total of 307 studies were identified after searching four
databases. After screening the titles and abstracts, 125
studies were extracted. The full texts of 29 studies were
reviewed, and 14 additional studies were excluded. Fif-
teen studies were included in this systematic review, and
twelve of these were included in the final analysis. The
study selection process is shown in Fig. 1. A summary of
the excluded studies [9, 21–33] and the reasons for the
exclusion of each study are listed in Table 1. The main
characteristics of the included studies are summarized in
Table 2.
Features of the included studies
Characteristics of the participants
Fifteen RCTs reported on the treatment of periodon-
tal defects, and these studies included 524 periodontal
intrabony defects treated in 399 patients (263 defects
in the intervention group, 261 defects in the control
group). The number of patients in each study ranged
from 10 [34, 36, 43] to 70 [11] and the number of
periodontal defects in each study ranged from 17 [36]
to 70 [11]. Most of the studies employed common ex-
clusion criteria, including patients with any systemic
illness known to affect periodontal healing; patients
exhibiting platelet deficiency, which can compromise
the PRP preparation; pregnant/lactating mothers;
immuno-compromised individuals; patients using
drugs that may impede wound healing; patients exhi-
biting hypersensitivity to any medication used in the
study; and individuals with poor oral hygiene. The
follow-up period in these studies ranged from 6 to
12 months.
Characteristics of the periodontal defects
The following clinical situation reported at baseline was
used in the selected studies: 1) a good level of oral hy-
giene (plaque index [PI] < 1); 2) the presence of an
intrabony defect at a PD > 5-6 mm after phase 1 therapy
(scaling and root planing [SPR]) and an intrabony com-
ponent of 2–4 mm as detected on radiography; 3) no
intrabony defects extending into a furcation area; and 4)
no teeth displaying furcation involvement. The types of
periodontal intrabony defects in the selected studies are
shown in Table 2.
Characteristics of the interventions
Various bone substitutes (deproteinized bovine bone
[35–37, 45, 46], β-tricalcium phosphate [42–44, 47],
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demineralized freeze-dried bone allograft [39, 40], bio-
active glass [38], and hydroxyapatite [34, 11]) were com-
bined with PRP in the selected studies. Four studies
[44–47] performed supplementary guided tissue regener-
ation (GTR) using membranes such as expanded poly-
tetrafluoroethylene membrane (e-PTFE) [45, 47] and
bio-absorbable collagen membrane (COL) [44, 46]. The
details regarding the method of PRP preparation, includ-
ing the type of cell separation device, the centrifugation
steps, the baseline and treatment platelet counts, and
the activators of coagulation, in the selected studies are
shown in Table 3.
Table 1 Summary of the excluded studies and the reason for their exclusion
Reference Reason for exclusion
Camargo et al. 2005 [9] Inappropriate control group (use of OFD instead of GTR + BM)
Rodrigues et al. 2011 [21] Inappropriate control group (use of PRP instead of ABM)
Yilmaz et al. 2011 [22] Inappropriate control group (use of PPP + BDX instead of BDX)
Yilmaz et al. 2010 [23] Inappropriate control group (use of PRP + BDX instead of BDX)
Pradeep et al. 2009 [24] Inappropriate control group (use of PRP instead of ABM/P-15)
Yamamiya et al. 2008 [25] Inappropriate control group (use of HA + PRP instead of HA + HCP)
Ilgenli et al. 2007 [26] Inappropriate control group (use of PRP instead of DFDBA)
Camargo et al. 2002 [27] Inappropriate control group (use of GTR instead of GTR + BM)
Pradeep et al. 2012 [28] Inappropriate control group (use of OFD instead of bone graft)
Yilmaz et al. 2009 [29] Not a randomized controlled clinical trial
Camargo et al. 2009 [30] Not a randomized controlled clinical trial
Czuryszkiewicz-Cyrana et al. 2006 [31] Not a randomized controlled clinical trial
Döri et al. 2008 [32] Used a biologic material (EMD)
Döri et al. 2013 [33] Used a biologic material (EMD)
ABM anorganic bone mineral, BDX bovine-derived xenograft, P-15 peptide-15, HCP human cultured periosteum, OFD open flap debridement, HA hydroxyapatite,
DFDBA demineralized freeze-dried bone allograft; BM bovine-derived porous bone mineral, EMD enamel matrix derivative
Fig. 1 Flow chart of the study selection process
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Table 2 Characteristics of the randomized trials reporting on the treatment of periodontal intrabony defects
Authors and publication
year





Intervention Control Intervention Control
Gupta G et al. 2014 [34] Split-mouth India 10 20 PRP + HA HA 10 10 1, 2, 3 12 mo Positive BOP, PD, CAL,
Okuda K et al. 2005 [11] Parallel Japan 70 70 PRP + HA HA 35 35 2, 3 12 mo Positive GI, BOP, PD, CAL, GR, DF
Hanna R et al. 2004 [35] Split-mouth US 13 26 PRP + BDX BDX 13 13 2, 3 6 mo Positive PD, CAL, GI, PI, REC, BOP
Ouyang XY et al. 2006 [36] Split-mouth China 10 17 PRP + ABB ABB 9 8 2, 3 12 mo Positive PI, PD, CAL, REC, Bone defect fill
Döri et al. 2009 [37] Parallel Hungary 30 30 PRP + ABB ABB 15 15 1,2 13 mo None PD, GR, CAL, PI, GI, BOP,
Demir et al. 2007 [38] Parallel Turkey 29 29 PRP + BG BG 15 14 1, 2, 3 9 mo None PD, CAL, GR, PI, GI, BOP,
Agarwal et al. 2014 [39] Split-mouth India 24 48 PRP + DFDBA DFDBA 24 24 2, 3 12 mo Positive PD, CAL, REC
Piemontese et al. 2008 [40] Parallel India 60 60 PRP + DFDBA DFDBA 30 30 2, 3 12 mo Positive GI, PI, PD, CAL, BOP, REC,
Harnack et al. 2009 [41] Split-mouth Germany 22 44 PRP + β-TCP β-TCP 22 22 2 6 mo Positive GI, PI, PD, CAL, BOP,
Özdemir et al. 2012 [ 43] Parallel Turkey 14 28 PRP + β-TCP β-TCP 14 14 2,3 7 mo None PD, CAL, GI, BOP,
Kaushick et al. 2007 [43]\ Split-mouth India 10 20 PRP + β-TCP + HA β-TCP + HA 10 10 2, 2–3, 3 6 mo Positive PD, CAL, GI, PI
Christgau et al. 2006 [44] Split-mouth Germany 25 50 PRP + β-TCP + GTR β-TCP + GTR 25 25 2, 2–3, 3 12 mo None PI, GI, BOP, PD, GR, CAL,
Döri, Huszar et al. 2007 [45] Parallel Hungary 24 24 PRP + ABB + GTR ABB + GTR 12 12 1-2, 2 12 mo None BOP, PD, CAL,
Döri et al. 2007 [46] Parallel Hungary 30 30 PRP + NBM + GTR NBM + GTR 15 15 1-2, 2, 3 12 mo None PD, GR, CAL, PI, GI, BOP,
Döri et al. 2008 [47] Parallel Hungary 28 28 PRP + β-TCP + GTR β-TCP + GTR 14 14 1-2, 2, 3 12 mo Positive PD, CAL, PI, GI, BOP, GR




















Centrifugation steps Activator (s) of coagulation Platelet count
Intervention Control
Gupta G et al. 2014 [34] PRP + HA HA Not
reported
Two (1200 r.p.m., 20 min & 2000
r.p.m., 15 min)
10 % CaCl2 mixed with human
thrombin
Not recorded
Okuda K et al. 2005 [11] PRP + HA HA Heraeus
Labofuge
300
Two (2400 r.p.m., 10 min & 3600
r.p.m., 16 min)
0.1 g of sodium alginate Not recorded directly; reference was made to
a previous study [48], Baseline: 257 × 103/μL ±
46 × 103/μL
Hanna R et al. 2004 [35] PRP + BDX BDX SmartPReP Two (2400 r.p.m., 10 min & 3600
r.p.m., 15 min)
1 mL of 10 % CaCl2, mixed with
1000 United States, Units of topical
thrombin
Not recorded
Ouyang XY et al. 2006
[36]
PRP + ABB ABB Universal
16R
centrifuge
Two (1220 r.p.m., 15 min & 3600
r.p.m., 15 min)
Sterile saline solution containing
10 % CaCl2 mixed with 100 U/mL
sterile bovine thrombin
Baseline: 189 × 103/μL ± 37 × 103/μL., Post
treatment: 680× 103/μL ± 103 × 103/μL
Döri et al. 2009 [37] PRP + ABB ABB Curasan
PRP kit
Two (1220 r.p.m., 15 min & 3600
r.p.m., 15 min)
Sterile saline solution containing
10 % CaCl2 mixed with 100 U/mL
sterile bovine thrombin
Not recorded directly; reference was made to
a previous study [49], Post treatment: 2519.6 ×
103/μL ± 834.3 × 103/μL
Demir et al. 2007 [38] PRP + BG BG Heraeus
Christ
Medifuge
Two (3000 r.p.m., 10 min & 3600
r.p.m., 10 min; or 200 g, 10 min
0.3 mL of 0.025 M CaCl2, mixed with
blood harvested from the surgical
site
Baseline: 189× 103/μL ± 37 × 103/μL, Post
treatment: 680 × 103/μL ± 103× 103/μL
Agarwal et al. 2014 [39],
Piemontese et al. 2008
[40]
PRP + DFDBA DFDBA SmartPReP Two (2400 r.p.m., 10 min & 3600
r.p.m., 15 min)
1 mL of 10 % CaCl2 mixed, with
1000 United States, Units of topical
thrombin
Not recorded
Harnack et al. 2009 [41] PRP + β-TCP β-TCP Curasan
PRP kit
Two (3169 r.p.m., 10 min & 4725
r.p.m., 15 min; or 900 g, 10 min &
2000 g, 15 min)
Blood harvested from the, surgical
site
Not recorded
Özdemir et al. 2012 [42] PRP + β-TCP β-TCP Curasan
PRP kit
Two (2400 r.p.m., 10 min & 3600
r.p.m., 15 min)
Not recorded Baseline: 290 × 103/μL ± 86 × 103/μL. Post
treatment: 1075× 103/μL ± 636 × 103/mL
Kaushick et al. 2007 [43] PRP + β-TCP + HA β-TCP + HA Not
reported
Two (5000 r.p.m., 10 min & 2000
r.p.m., 10 min)
10 % CaCl2 mixed with an equal
volume of saline.
Baseline: 200 × 103/μL Post treatment: 1250 ×
103/μL.
Christgau et al. 2006
[44]
PRP + β-TCP + GTR β-TCP + GTR Spectra cell
separator
Not recorded 0.5 ml of a sterile 10 % CaCl2
solution
Baseline: 273× 103/μL ± 56 × 103/μL, Post
treatment: 2134 × 103/μL ± 782× 103/μL
Döri et al. 2007 [45],
Döri et al. 2007 [46] Döri
et al. 2008 [47]
PRP + ABB + GTR PRP
+ NBM + GTR PRP
+ β-TCP + GTR
ABB + GTR




Two (1220 r.p.m., 15 min & 3600
r.p.m., 15 min)
Sterile saline solution containing
10 % CaCl2 mixed with 100 U/mL
sterile bovine thrombin
Not recorded directly; reference was made to
a previous study [49], Post treatment: 2519.6 ×
103/μL ± 834.3 × 103/μL
SmartPReP; Harvest Technologies Corp, Plymouth, MA, USA. Heraeu + A1:G16s Labofuge 300; Kendro Laboratory Products, Osterrode, Germany. Universal 16R centrifuge Hettich, Germany. Heraeus Christ Medifuge;















The increase in CAL was significantly greater in the
intervention group treated with PRP than in the control
group, as determined through the random-effects model,
which included twelve studies [11, 35–40, 43–47]. PRP
showed a significantly positive effect on periodontal
intrabony defect treatment (CAL: WMD 0.76 mm,
95%CI = 0.34 to 1.18 mm, P = 0.0004) (Fig. 2). No defini-
tive publication bias was detected in the meta-analysis of
the studies reporting on the change in CAL (Egger’s test
t value = −1.64, 95%CI = −6.09 to 0.92, P = 0.13), and the
funnel plot appeared to be symmetric, indicating an ab-
sence of publication bias (Fig. 3).
Change in PD
The PD reduction was significantly greater in the inter-
vention group treated with PRP than in the control
group based on the random-effects model, which in-
cluded twelve studies (PD: WMD 0.53 mm, 95%CI =
0.21 to 0.85 mm, P = 0.001) (Fig. 4).
Subgroup analyses
The results of our subgroup meta-analysis of the GTR
technique indicated that the CAL gains of patients who
underwent GTR and patients who did not undergo GTR
remained significantly different. As demonstrated by the
four studies [44–47] that used PRP together with GTR,
PRP had an insignificant effect on the treatment (CAL:
WMD 0.08 mm, 95%CI = −0.30 to 0.46 mm, P = 0.67).
However, the eight studies [11, 35–40, 43] that used PRP
without GTR showed that PRP had a significant positive
effect on periodontal intrabony defect treatment (CAL:
WMD 1.22 mm, 95%CI = 0.88 to 1.57 mm, P < 0.00001)
(Fig. 5).
An additional subgroup meta-analysis was performed
on the study design. A significant difference in outcome
was found between the different study designs. In the
seven parallel-group studies [11, 37, 38, 40, 45–47], the
mean difference in CAL gain between the intervention
and control groups was 0.45 mm (95%CI = −0.05 to
0.94 mm), whereas in the five split-mouth studies [35,
36, 39, 43, 44], the mean difference in CAL gain between
the intervention and control groups was 1.20 mm
(95%CI = 0.72 to 1.69 mm) (Fig. 6)
Meta regression
Random-effect meta‑regression analyses were used to
explore the possible sources of heterogeneity among
the studies. A separate univariate meta-regression
model utilizing GTR as a predictor was significant for
CAL (β = 0.296, 95%CI = −1.759 to −0.673, P = 0.001),
indicating that the use of GTR has a significant influ-
ence on study outcomes. This variable explained all
model heterogeneity, with no significant residual het-
erogeneity. No significant influences were observed
for study design or the type of control (P > 0.05 for
each). The results of the meta-regression analyses are
shown in Table 4.
Assessment of risk of bias
Of the included RCTs that evaluated the treatment of
periodontal defects, three [11, 35, 40] were classified
as having a low risk of bias, whereas ten [34, 36–39,
41–43, 45, 46] and two [44, 47] were determined to
have a moderate and high risk of bias, respectively.
The risk-of-bias graph presents a review of the au-
thors’ judgments regarding each risk-of-bias item, and
the values are presented as percentages across all in-
cluded studies (Fig. 7).
Discussion
The present systematic review aimed to assess the ef-
ficacy of PRP in the surgical treatment of periodontal
intrabony defects based on randomized trials and re-
ports that the use of PRP as an adjunct to a graft
procedure yielded a significantly greater CAL gain
and a PD reduction compared with the control treat-
ment. Subgroup meta-analyses showed that the level
of CAL gain was significantly higher in patients who
were not treated with the GTR technique than in
Fig. 2 Meta-analysis of the mean difference (MD) in CAL gain due to the treatment of periodontal intrabony defects
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those who were. Moreover, a significant difference in
observed outcomes was found for different study de-
signs. We performed a meta-regression analysis to as-
sess how the use of GTR, different study designs and
the type of control affected heterogeneity. Only the
use of GTR, which explained 100 % of the heterogen-
eity among the studies that assessed CAL gain, was
identified as a source of heterogeneity.
In this study, we used a random-effects model for the
meta-analysis, which assumed that the true effects were
normally distributed. Overall, as determined primarily
based on the results of the primary outcome variable
(change in CAL), four of the RCTs [44–47] demon-
strated that the addition of PRP to a specific GTR tech-
nique, i.e., β-TCP + GTR (e-PTFE) [44, 47], ABB + GTR
(COL) [45], or NBM +GTR (COL) [46], failed to provide
a statistically significant additive benefit to the manage-
ment of periodontal intrabony defects. However, other
RCTs [11, 34–43] reported that such adjunctive positive
outcomes may result from the combination of PRP with
other treatments, specifically HA [34, 11], BDX [35],
ABB [36, 37], or DFDBA [39, 40]. A possible explanation
for this finding may be that the control group (bone sub-
stitute + GTR) achieved a remarkable CAL gain and PD
reduction and that the potential positive influence of
PRP may be masked by the significantly high contribu-
tion of the regeneration materials on the clinical out-
comes. Our results also confirmed the findings of other
studies [12, 17]. In addition to serving as an indicator of
positive outcome of periodontal regenerative procedures,
PD reduction could also represent an important param-
eter in patient care because it directly reflects the ability
to evaluate a treated area during maintenance appoint-
ments. According to the outcome variable (change in
PD reduction), PRP therapy had a significant positive
effect on periodontal intrabony defect treatment (the
mean difference in PD reduction was 0.53 mm, 95%CI =
0.22 to 0.85 mm, P = 0.001).
Our analysis showed a significant difference be-
tween studies adopting a split-mouth design and
those adopting a parallel design, and this finding in-
dicates that different study designs are not equally
Fig. 3 Egger’s publication bias plot a and Begg’s funnel plot b of studies that evaluated CAL gain due to the treatment of periodontal
intrabony defects
Fig. 4 Meta-analysis of the mean difference (MD) in PD reduction due to the treatment of periodontal intrabony defects
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effective in assessing the clinical efficacy of PRP.
The attractiveness of the split-mouth design is the
substantial reduction of inter-subject variability from
the estimates of the treatment effect. However, the
parallel-group design, in which all sites of one indi-
vidual receive the same randomized treatment, is not
only the simplest but also the most popular design
used in clinical trials. A parallel design should be
endorsed for the statistical comparison of outcome
variables (i.e., CAL gain, PD reduction, and radio-
graphic bone level) between the experimental and
control groups. In contrast to the recommendations
by Lesaffre et al. and the Cochrane Oral Health
group, most systematic reviews did not evaluate
split-mouth and parallel-arm trials separately in sub-
group analyses [50]. Smaïl-Faugeron et al. reported a
meta-epidemiological study that did not provide suf-
ficient evidence for systematic differences in inter-
vention effect estimates between split-mouth and
parallel-arm RCTs for either continuous or binary
outcome data [51].
The natural limitations involved in the preparation
and application of PRP played an important role in eval-
uations of the efficacy of the adjunctive use of PRP in
Fig. 5 Subgroup analysis of the mean difference (MD) in CAL gain among studies that evaluated the use of PRP with or without the concomitant
use of GTR
Fig. 6 Subgroup analysis of the mean difference (MD) in CAL gain among studies that utilized a split-mouth design or a parallel design
for analysis of the treatment of periodontal intrabony defects
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the management of periodontal intrabony defects. Some
studies reported that differences in the level and the pro-
portion of various growth factors may be detected using
different commercially available systems and that this
difference in the results may affect the outcomes [49, 52,
53]. Commercially available PRP systems can enrich
platelets by two- to five-fold or even up to 10-fold,
which is higher than the platelet concentration in whole
blood. Additionally, researchers have reported that the
effect of PRP is below the desired level at a low platelet
concentration but that an inhibitory effect of PRP is ob-
served at much higher PRP concentrations in whole
blood [52, 53].
An important strength of our systematic review was
the study selection because we used a range of data-
bases and strict inclusion criteria for selecting the
studies. There are also several limitations to this re-
view. First, in this systematic review, we failed to
undertake manual searches or identify unpublished re-
search. It has been reported [54, 55] that the exclu-
sive use of electronic data sources may not be a
sufficient search strategy. This limitation may lead to
a selection bias. Second, the majority of the RCTs in-
corporated an appropriate methodological approach,
such as the definition of inclusion/exclusion criteria, the
selection of suitable control groups, and appropriate
methods of statistical interpretation. However, most of the
RCTs had not performed sample size estimation before
beginning their studies, which limits the evaluation of au-
tologous PRP efficacy. Third, despite these findings, many
of the RCTs selected in our analysis included small popu-
lation sizes; therefore, additional large-scale clinical trials
are required to clarify the long-term benefits of PRP. Add-
itional research in this field is needed to consider specific
factors, including sample size calculation and the alloca-
tion concealment and blinding methods used. Future
studies planning to assess the adjunctive use of PRP in the
treatment of periodontal intrabony defects should pay
special attention to aesthetics, the rate of wound heal-
ing, and a subjective index as outcome variables be-
cause few of the selected RCTs reported these types
of data.
Conclusion
The adjunctive use of PRP together with conventional
grafting procedures may be a beneficial treatment ap-
proach. However, when combined with the use of a regen-
erative technique, such as GTR, the beneficial effect of
PRP on the treatment of intrabony defects is negligible.
Fig. 7 Risk-of-bias graph. The determinations made by the review authors regarding each risk-of-bias item are presented as percentages across all
included studies
Table 4 Univariate meta-regression analyses of potential sources of heterogeneity
Heterogeneity
factor




Use of GTR 0.296 0.244 −4.990 0.001 −1.759 −0.673 100.00 7.48
Study design 0.476 0.366 −2.030 0.070 −1.557 0.072 38.36 55.39
Type of control
Allograft 2.461 0.570 1.580 0.149 −0.389 2.190 10.06 64.10
Synthetic 1.316 0.452 0.610 0.558 −0.747 1.296
Note: Xenograft dropped because of collinearity. Adjusted R2 (%) = Proportion of between-study variance explained. I2res (%) = % of residual variation due
to heterogeneity
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